DURECT (DRRX) Director Reports 5,500-Share Purchase and Option Grant
Rhea-AI Filing Summary
Insider grant and purchase reported: Director Gail M. Farfel reported a transaction in DURECT CORP (DRRX) showing acquisition of both common stock and a stock option on 09/10/2025. The filing shows 5,500 shares of common stock acquired at $1.22 per share, bringing Ms. Farfel's direct holdings to 15,500 shares. The filing also discloses a stock option granted on the same date with a $1.22 exercise price covering 5,500 underlying shares; the option becomes fully exercisable one day before the first anniversary of grant and expires on 09/25/2034. The Form 4 is signed 09/11/2025 and identifies Ms. Farfel as a director filing individually.
Positive
- Director alignment: Ms. Farfel acquired shares and received an option, which aligns incentives with shareholders through time-based vesting.
- Clear vesting schedule: The option vests 100% one day before the first anniversary, providing service-based retention rather than immediate dilution.
Negative
- None.
Insights
TL;DR: Director received synchronized equity and option grant, aligning long-term incentives without immediate large dilution.
The reported transaction shows a director-level equity grant and matching option covering 5,500 shares at a $1.22 price, with vesting fully occurring one year from grant. From a governance perspective, time-based vesting tied to continued service is a standard retention mechanism that aligns the director with shareholder interests over the vesting period. The option's long expiration to 09/25/2034 provides extended upside potential contingent on future stock performance. This filing is routine for compensation-related grants and does not itself reveal operational changes.
TL;DR: Insider acquired 5,500 shares and received an option for 5,500 shares at $1.22; transaction appears procedural and not material to capital structure.
The Form 4 discloses a purchase of 5,500 common shares at $1.22 and a contemporaneous option grant exercisable after one year for the same number of shares. Post-transaction direct beneficial ownership is reported as 15,500 shares. For investors, the amounts are modest relative to typical market-cap impacts; the combined grant and purchase indicate management/director alignment but are unlikely to meaningfully change share count or valuation near-term.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (right to buy) | 5,500 | $0.00 | $0.00 |
| Exercise | Common Stock | 5,500 | $1.22 | $7K |
Footnotes (1)
- F1. 100% of the total number of shares subject to this option grant shall vest and become exercisable on the day before the first anniversary of the date of grant, subject to the Reporting Person continuing to provide services to the Company through the vesting date.
AI-generated analysis. How Rhea-AI works. Not financial advice.
